Anti-GBM and Complement-Mediated Disease: Different Immune Routes

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Pulmonary–renal anti-GBM disease is an emergency; complement-mediated disease requires a different diagnostic pathway.

Linear antibody binding differs from complement-driven injury. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Linear antibody binding differs from complement-driven injury. . Urgent anti-GBM evaluation and a complement-pattern workup are different pathways; use serology and biopsy together. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Recognize the anti-GBM emergency

Rapid creatinine rise with glomerular hematuria and possible hemoptysis/hypoxemia should prompt urgent nephrology evaluation. Pulmonary hemorrhage may occur even without striking hemoptysis.

Send time-critical tests

Obtain anti-GBM antibodies, ANCA, urinalysis/protein quantification, blood count, creatinine, and appropriate chest assessment. Arrange kidney biopsy when feasible. Strong suspicion of organ-threatening disease warrants specialist treatment decisions before every result returns.

The biopsy patterns differ

Anti-GBM disease classically produces linear IgG staining along the basement membrane. C3-dominant staining suggests a complement-mediated pattern; immune-complex deposits raise another differential. The staining pattern guides further testing.

Understand anti-GBM treatment goals

Plasma exchange removes circulating antibody; immunosuppression reduces further production and inflammation. Kidney recovery potential, dialysis dependence, biopsy damage, and pulmonary hemorrhage affect decisions; no single creatinine cutoff substitutes for specialist assessment.

Investigate a complement pattern

C3/C4 levels, infection assessment, monoclonal protein studies, and specialist complement testing help distinguish triggers and mechanisms. A low C3 alone does not prove C3 glomerulopathy or select a complement inhibitor.

Worked distinction

Hematuria and AKI with pulmonary hemorrhage needs an urgent anti-GBM/ANCA pathway. Isolated low C3 with persistent proteinuria needs a pathology-led cause search. These presentations should not share one generic immunosuppression algorithm.

Supporting evidence

Continue learning